We have had many articles that look at why certain people develop insulin resistance more easily than others. There are many different theories as to why this resistance occurs, but in every case no one has offered a real solution to this problem. In our second special report on the …
Read More »Yearly Archives: 2017
A New Paradigm in the Understanding and Treatment of the Metabolic Syndrome, Part 2
As concluded in the previous newsletter in this series, “Evolutionary selection for insulin resistance in a cyclic environment: brain clocks and control of peripheral metabolism” the brain is equipped with circadian neurophysiological mechanisms to induce (and reverse) the insulin resistant state that evolved as a survival strategy against ensuing environmental stresses such as prolonged (seasonal) lack of food availability. A central facilitator of this insulin resistance induction is a diminution of the circadian peak in dopaminergic activity at the SCN. Neurotoxin induced destruction of these dopaminergic projections to the clock of insulin sensitive animals induces marked insulin resistance and glucose intolerance without alterations in food consumption.
Read More »Impact of Bromocriptine-QR Therapy on Cardiovascular Outcomes in Type 2 Diabetes Mellitus Subjects on Metformin
Given the potential for CVD risk reduction associated with metformin and B-QR therapy individually, the present study explored the effect of add-on B-QR vs placebo to metformin on CVD outcomes in T2DM subjects.
Read More »Jan. 10, 2017
Five or six years ago, the widespread advertising of $4 dollar drug programs was in the wheelhouse of every pharmacy, and there were hundreds of drugs on the list. Since then the list has gotten much shorter and the number of pharmacies advertising them has decreased. Part of the reason …
Read More »How to Best Add or Adjust Medications
Man, 51 years of age, type 1 diabetes for 32 years. Patient also has history of Class II obesity, CVA, MI and insulin resistance. Patient referred to Obesity Center for weight loss. A1c was 8.2%. Plan was to start Symlin. Symlin was added at 30mcg daily before dinner. I recommended he get a CGM. He did.
Read More »Altamash Shaikh Part 1, Diabetes in India
Dr. Altamash Shaikh talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 1 of this Exclusive Interview, Dr. Shaikh explains the current state of diabetes in India and the needs required to help this population to manage this condition.
Read More »EMPA-REG Outcome Trial, Part 4
In this week's Homerun Slides, the vital stats of patients on the placebo and empagliflozin 10- and 25-gram study.
Read More »International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #57: Mechanisms of Insulin Signal Transduction Part 1 of 8
Fuel homeostasis: The peptide hormone insulin is secreted from pancreatic beta cells, and exerts a broad spectrum of anabolic effects in multiple tissues. In response to a meal, insulin stimulates uptake and storage of carbohydrate, fat, and amino acids, while, at the same time, antagonizing the catabolism of these fuel reserves.
Read More »Jan. 7, 2017
The ADA has announced their new Standards of Care for 2017 and they are taking a more global approach to A1C, CVD and hypoglycemia. When it comes to CVD, there is a bigger push to get patients to improve blood pressure levels. They recommend more widespread use of ARB’s and …
Read More »Preventing CV Death in Patients With Diabetes
What do we need to tell our patients about preventing the risk for death?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.